ClinicalTrials.gg
Not yet recruitingNCT06895460Updated Jun 5, 2025

A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)

A Phase 3 interventional study of Budesonide Formoterol and Placebo in Bronchial Asthma, sponsored by The First Affiliated Hospital with Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
99th of 182
198 · median 203
Started
2025
with 31 others
Phase 3
47 of 251
13 open now
Primary completion
2027-06
later than 48 of 95 live
Registered
199th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 99th largest by planned enrollment of the 182 interventional ones that give a count, is one of 32 that started in 2025, is one of 47 in phase 3, reaches primary completion later than 48 of the 95 other live ones, and was the 199th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on the Treatment of Bronchial Asthma with Budesonide Formoterol Combined with Immune Modulators (Staphylococcus and Neisseria Tablets)

Read the detailed description

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial. A total of 198 participants with bronchial asthma are planned to be enrolled and randomized in a 1:1 ratio to the experimental group and the control group. The experimental group will receive Budesonide Formoterol Powder for Inhalation plus immune modulators (Staphylococcus and Neisseria Tablets), while the control group will receive Budesonide Formoterol Powder for Inhalation plus placebo. The treatment period is 3 months for both groups, followed by a 3-month follow-up after treatment.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 14 years, male or female;
  2. Confirmed diagnosis of asthma at least 6 months prior to screening;
  3. Patients with uncontrolled asthma (according to the 2024 GINA guidelines-asthma control level classification criteria, patients with partially controlled and uncontrolled asthma);
  4. Within the past 6 months, at least one of the following positive test results for lung function:

    • Positive bronchodilator test with an increase in of ≥12%, and an absolute increase in FEV1 of ≥200 ml;
    • Positive bronchial provocation test or exercise challenge test;
    • Peak expiratory flow (PEF) variability over 2 weeks with a daily variation rate of ≥20% or a weekly average variation rate of ≥10%;
    • Significant improvement in lung function after 4 weeks of asthma treatment, with an increase in FEV1 of ≥12%, an absolute increase in FEV1 of ≥200 ml, or an improvement in PEF of ≥20%;
  5. Before the first administration of the study drug, the patient has good function of major organs and no to ICS + LABA treatment;
  6. The participant (or their legal representative) must sign and date the form, indicating their understanding of the study's purpose and the procedures involved, and their willingness to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of severe asthma (according to the definition in the Guidelines for the Prevention and Treatment of Bronchial Asthma (2024 Edition));
  2. Patients in the acute exacerbation phase who may require intravenous/oral ;
  3. Patients with rheumatology and immunology conditions;
  4. Atypical asthma or comorbidities such as pulmonary tuberculosis, , bronchiectasis, pulmonary embolism, severe respiratory failure, or other respiratory system diseases;
  5. Individuals with significant diseases other than bronchial asthma. Significant diseases are defined as conditions that, in the investigator's judgment, may place the participant at risk or affect the study results, such as severe cardiovascular, cerebrovascular, hepatic, renal, hematologic diseases, , psychiatric disorders, immune system diseases, or pulmonary organic functional impairments;
  6. Individuals allergic to the study drug or corticosteroids;
  7. Participation in another clinical trial within 30 days prior to screening or currently ongoing;
  8. Use of immune modulators (including thymosin, thymopeptides, interferon, transfer factor, Bacillus Calmette-Guérin polysaccharides, any type of bacterial extracts, such as Biostim, bacterial lysate capsules) within 30 days prior to the use of the study drug or during the study period;
  9. Women who are currently pregnant or breastfeeding, or women of who cannot use during the study period;
  10. The participant is deemed unsuitable for study observation by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
198 participants (estimated)

Study arms

  • Placebo comparator
    Budesonide Formoterol combined with placebo

    Drug: Budesonide Formoterol · Drug: Placebo

  • Experimental
    Budesonide Formoterol Combined with Immune Modulators (Staphylococcus and Neisseria Tablets)

    Drug: Budesonide Formoterol · Drug: Immune Modulators (Staphylococcus and Neisseria Tablets)

Interventions

  • DrugBudesonide Formoterol

    Investigator Selection

  • DrugPlacebo

    Placebo: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months

  • DrugImmune Modulators (Staphylococcus and Neisseria Tablets)

    Drug page: Immunologic FactorsStudies of Immunologic FactorsImmunologic Factors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Staphylococcus and Neisseria Tablets: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months

06

What researchers measure

Primary outcomes

  1. The overall asthma control rate at 12 weeks of treatment

    The overall control rate = (number of well-controlled cases + number of partially controlled cases) / total number of cases × 100%

    Time frame: week 12

Secondary outcomes

  1. The overall asthma control rate at 24 weeks of treatment

    The overall control rate = (number of well-controlled cases + number of partially controlled cases) / total number of cases × 100%

    Time frame: week 24

  2. Number of acute asthma exacerbations

    Time frame: Month 1, Month 2, Month 3, Month 4, Month 5, Month 6

  3. Changes in Asthma Control Test (ACT) scores

    The minimum and maximum scores of the Asthma Control Test are 5 and 25 points respectively. The higher the ACT score, the better the asthma control.

    Time frame: Month 1, Month 2, Month 3, Month 4, Month 5, Month 6

  4. Changes in lung function indicators compared to baseline

    Changes in PEF

    Time frame: Month 3, Month 6

  5. Five-point Asthma Quality of Life Scoring

    The minimum and maximum total scores of the 5-point asthma quality of life assessment are 35 and 175 points respectively. The higher the score, the better the patient's quality of life.

    Time frame: Month 3, Month 6

  6. Adverse events (AEs)

    Time frame: Month 1, Month 2, Month 3, Month 4, Month 5, Month 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Jun 2027, 24 months later.

Of 32 non-industry phase 3 interventional studies under Asthma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 24 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 26, 2025
StartEst.
Jun 20, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895460
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Jun 20, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jun 5, 2025

Study contacts

Xin Yao, Chief physician
Contact
xyao1998@126.com
+8618651608881

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunologic Factors

Start the discussion